90.33
前日終値:
$94.39
開ける:
$90.14
24時間の取引高:
9.30M
Relative Volume:
1.56
時価総額:
$280.06B
収益:
$58.07B
当期純損益:
$9.40B
株価収益率:
30.00
EPS:
3.0113
ネットキャッシュフロー:
$9.87B
1週間 パフォーマンス:
-4.37%
1か月 パフォーマンス:
-1.07%
6か月 パフォーマンス:
+31.39%
1年 パフォーマンス:
+35.71%
Astrazeneca PLC Stock (AZN) Company Profile
名前
Astrazeneca PLC
セクター
電話
44 20 3749 5000
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AZN
Astrazeneca PLC
|
90.33 | 292.66B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca PLC (AZN) 最新ニュース
Astrazeneca expands China cell therapy footprint with Abelzeta CAR T - BioWorld MedTech
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates - TechStock²
AstraZeneca to delist from Nasdaq, join NYSE in February - Reuters
Why Is AstraZeneca Stock Trading Lower Today?AstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE - GuruFocus
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January - Investing.com
AstraZeneca to complete direct listing in NY on February 2 - marketscreener.com
AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial - Finviz
AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate - Chartmill
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE - GuruFocus
AstraZeneca To Move Nasdaq Listing To NYSE - DirectorsTalk Interviews
AstraZeneca Plans NYSE Listing for Shares, US Debt - Mirage News
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treat - GuruFocus
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus - TechStock²
Bioconjugation Market Size to Hit USD 14.51 Billion by 2033, Driven by the Increasing Demand for Targeted Therapeutics – SNS Insider - GlobeNewswire Inc.
AstraZeneca's Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Finviz
AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Yahoo Finance UK
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy - Pharmaceutical Technology
Prediction: analysts think the AstraZeneca share price will do this in 2026 - The Motley Fool UK
AbelZeta and AstraZeneca Reach $630 Million Acquisition Agreement - Intellectia AI
AstraZeneca PLC agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million. - marketscreener.com
Trend Review: Does AstraZeneca PLC Depositary Receipt have a sustainable dividendEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
AstraZeneca share price steadies after Thursday drop as traders eye Nasdaq-100 reshuffle - TechStock²
AstraZeneca’s Cell Therapy Manufacturing Facility, Maryland, USA - Pharmaceutical Technology
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
Deutsche Bank Maintains ASTRAZENECA PLC(AZNCF.US) With Sell Rating, Raises Target Price to $147.24 - 富途资讯
AZN Stock Price, Forecast & Analysis | ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) - Chartmill
AstraZeneca (AZN) Acquires Modella AI to Boost Cancer Research - GuruFocus
AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development - Intellectia AI
JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
What Makes AstraZeneca (AZN) a Strong Growing Company? - Insider Monkey
AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference - Yahoo Finance
Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares - MarketBeat
AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition - Pharmaceutical Technology
Manning & Napier Advisors LLC Sells 390,342 Shares of AstraZeneca PLC $AZN - MarketBeat
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - marketscreener.com
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Market Overview: Whats AstraZeneca PLC Depositary Receipts historical returnMarket Performance Recap & Intraday High Probability Alerts - baoquankhu1.vn
AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com
AstraZeneca stock rating reiterated at Buy by Guggenheim ahead of Q4 results - Investing.com UK
AstraZeneca Buys US-based Modella AI - marketscreener.com
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
AstraZeneca acquires AI firm to boost research - breakingthenews.net
Astrazeneca PLC (AZN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):